MBX Biosciences (MBX) Total Liabilities (2023 - 2026)

MBX Biosciences has reported Total Liabilities for 4 years, with the latest figure at $14.9 million in Q1 2026.

• Quarterly Total Liabilities rose 42.28% year-over-year to $14.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.9 million (up 42.28% YoY) and the FY2025 annual result came in at $15.9 million, up 43.52% from the prior year.
• Total Liabilities declined to $14.9 million in Q1 2026 per MBX's latest filing, from $15.9 million in the prior quarter.
• Over five years, Total Liabilities peaked at $15.9 million in Q4 2025 and troughed at $4.3 million in Q4 2023.
• A 4-year average of $11.6 million and a median of $11.7 million in 2024 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2024 and 2025: Total Liabilities soared 158.52% in 2024, then gained 13.65% in 2025.
• Over 4 years, Total Liabilities stood at $4.3 million in 2023, then surged by 158.52% to $11.1 million in 2024, then jumped by 43.52% to $15.9 million in 2025, then declined by 6.13% to $14.9 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $14.9 million, $15.9 million, and $12.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.